| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/21/2023 | 153.16% | Maxim Group | → $2 | Initiates Coverage On | → Buy |
What is the target price for Lexaria Bioscience (LEXX)?
The latest price target for Lexaria Bioscience (NASDAQ: LEXX) was reported by Maxim Group on July 21, 2023. The analyst firm set a price target for $2.00 expecting LEXX to rise to within 12 months (a possible 153.16% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lexaria Bioscience (LEXX)?
The latest analyst rating for Lexaria Bioscience (NASDAQ: LEXX) was provided by Maxim Group, and Lexaria Bioscience initiated their buy rating.
When is the next analyst rating going to be posted or updated for Lexaria Bioscience (LEXX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lexaria Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lexaria Bioscience was filed on July 21, 2023 so you should expect the next rating to be made available sometime around July 21, 2024.
Is the Analyst Rating Lexaria Bioscience (LEXX) correct?
While ratings are subjective and will change, the latest Lexaria Bioscience (LEXX) rating was a initiated with a price target of $0.00 to $2.00. The current price Lexaria Bioscience (LEXX) is trading at is $0.79, which is within the analyst's predicted range.
